The research compound in Egrifta^®

Egrifta^® is a HIV-associated lipodystrophy medicine from Theratechnologies. Its active compound is Tesamorelin — which is what this catalogue supplies, as a research material.

This is not Egrifta^®, and NOVALYTE LABS has no affiliation with Theratechnologies. We supply the compound Tesamorelin for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Egrifta^® is a trademark of Theratechnologies, referenced here only to identify the compound.

Egrifta is the brand under which tesamorelin is marketed, for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, stabilised against enzymatic degradation, and acts on the pituitary rather than supplying growth hormone directly.

Tesamorelin is supplied here as a research material, not as the branded medicine.

Tesamorelin in this catalogue